mRNA-1273 vaccine (Moderna): a better option than BNT162b2 (Pfizer) in kidney transplant recipients and dialysis patients?

With the roll-out of coronavirus disease 2019 (COVID-19) vaccines, it has become clear that vaccinating the majority of the population worldwide will be the most important element to control and manage the ongoing COVID-19 pandemic. Several reports have shown diminished immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in both kidney transplant recipients (KTRs) and dialysis patients (DPs), as evidenced in a recent narrative review [1]. Furthermore, two recent articles have included comparisons between the immunogenicity of the mRNA-1273 (Moderna) versus the BNT162b2 (Pfizer) vaccine in these populations [2, 3]. Boyarsky et al. [3] studied a cohort of solid organ transplant recipients, including KTRs, and reported lower seroconversion rates after receiving the Pfizer vaccine. Stumpf et al. [2] also described lower seroconversion rates in KTRs and DPs receiving the Pfizer vaccine. However, none of these articles reported the titers...